capivasertib,AZD5363
astrazeneca,otsuka
['capivasertib', 'biomarker']
#asco2022 jones faktion randomized phase 2 of fulvestrant +\- akt inhibitor capivasertib. addition of capivasertib increases pfs of 10.3 vs 4.8 mo. os 29.3 vs 23.1 mo. biomarker ngs results showed pathway alterations in 25% of pts.
Professor of Medicine, Stanford University; breast cancer doc